Clinical Trials · NCT02100475
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 31
- Start date
- Apr 2014
- Locations
- 60 sites, 10 countries
- Primary endpoint
- Change From Baseline in HbA1c (Glycosylated Haemoglobin)